Verona Pharma to Present at Jefferies London Healthcare Conference

11/5/24 2:00:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $VRNA alert in real time by email

LONDON and RALEIGH, N.C., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company") announces that senior management will present a company overview at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 6:30 a.m. ET / 11:30 a.m. GMT.

A webcast of the event will be available on the Events and Presentations link on the Investors page of the Company's website, www.veronapharma.com.

For further information please contact:

Verona Pharma plc	Tel: +1-844-341-9901
Victoria Stewart, Senior Director of Investor Relations and Communications	[email protected]
Argot Partners (US Investor Enquiries)	Tel: +1-212-600-1902 [email protected]
Ten Bridge Communications International / US Media Enquiries	Tel: +1-781-316-4424 [email protected]
Wendy Ryan

About Verona Pharma

Verona Pharma is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of chronic respiratory diseases with significant unmet medical needs. Ohtuvayre^TM (ensifentrine) is the Company's first commercial product and the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule. Ensifentrine has potential applications in non-cystic fibrosis bronchiectasis, cystic fibrosis, asthma and other respiratory diseases. For more information, please visit www.veronapharma.com.

Get the next $VRNA alert in real time by email

Recent Analyst Ratings for

$VRNA

Date	Price Target	Rating	Analyst
4/28/2025	$100.00	Buy	TD Cowen
4/21/2025	$80.00	Overweight	Cantor Fitzgerald
1/10/2025	$68.00	Buy	ROTH MKM
10/3/2024	$50.00	Overweight	Wells Fargo
5/22/2023	$35.00 → $38.00	Buy	Jefferies
9/19/2022	$27.00	Outperform	Wedbush
8/26/2022	$31.00	Overweight	Piper Sandler
11/12/2021	$18.00 → $23.00	Buy	Canaccord Genuity

More analyst ratings

Verona Pharma to Present at Jefferies London Healthcare Conference

Chat with this insight

Recent Analyst Ratings for $VRNA

$VRNA Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Medical Officer Rickard Kathleen A. sold $1,014,343 worth of Ordinary Shares (114,984 units at $8.82), decreasing direct ownership by 4% to 2,546,472 units (SEC Form 4)

Chief Medical Officer Rickard Kathleen A. sold $440,350 worth of Ordinary Shares (49,200 units at $8.95) and converted options into 50,000 units of Ordinary Shares, increasing direct ownership by 0.03% to 2,661,456 units (SEC Form 4)

Chief Financial Officer Hahn Mark W sold $5,311,479 worth of Ordinary Shares (587,008 units at $9.05) and converted options into 200,000 units of Ordinary Shares, decreasing direct ownership by 3% to 13,078,992 units (SEC Form 4)

$VRNA Financials

Live finance-specific insights

Verona Pharma Reports First Quarter 2025 Financial Results and Provides Corporate Update

Verona Pharma to Report First Quarter 2025 Financial Results and Provide Corporate Update

Verona Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

$VRNA Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Ebsworth David R bought $88,800 worth of Ordinary Shares (20,000 units at $4.44), increasing direct ownership by 2% to 940,003 units (SEC Form 4)

Director Ebsworth David R bought $188,881 worth of Ordinary Shares (39,360 units at $4.80), increasing direct ownership by 4% to 920,003 units (SEC Form 4)

Director Ackermann Christina bought $198,386 worth of Ordinary Shares (41,880 units at $4.74) (SEC Form 4)

$VRNA Press Releases

Fastest customizable press release news feed in the world

Verona Pharma to Present Seven Analyses of the Phase 3 ENHANCE Studies in COPD at ATS 2025

Verona Pharma Reports First Quarter 2025 Financial Results and Provides Corporate Update

Verona Pharma to Report First Quarter 2025 Financial Results and Provide Corporate Update

$VRNA Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

TD Cowen initiated coverage on Verona Pharma with a new price target

Cantor Fitzgerald initiated coverage on Verona Pharma with a new price target

ROTH MKM initiated coverage on Verona Pharma with a new price target

$VRNA SEC Filings

SEC Form 144 filed by Verona Pharma plc

SEC Form 144 filed by Verona Pharma plc

SEC Form 144 filed by Verona Pharma plc

$VRNA Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Verona Pharma plc

Amendment: SEC Form SC 13G/A filed by Verona Pharma plc

SEC Form SC 13G filed by Verona Pharma plc

$VRNA Leadership Updates

Live Leadership Updates

Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board

Verona Pharma Reports First Quarter 2021 Financial Results and Provides Corporate Update

Recent Analyst Ratings for
$VRNA

$VRNA
Insider Trading

$VRNA
Financials

$VRNA
Insider Purchases

$VRNA
Press Releases

$VRNA
Analyst Ratings

$VRNA
SEC Filings

$VRNA
Large Ownership Changes

$VRNA
Leadership Updates